Allosteric modulation of G-protein coupled receptors

被引:93
作者
Jensen, AA
Spalding, TA
机构
[1] Danish Univ Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen, Denmark
[2] ACADIA Pharmaceur Inc, San Diego, CA USA
关键词
G-protein coupled receptors (GPCRs); allosteric modulation; allosteric modulator; potentiation; inhibition;
D O I
10.1016/j.ejps.2003.11.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The superfamily of G-protein coupled receptors (GPCRs) has more than 1000 members and is the largest family of proteins in the body. GPCRs mediate signalling of stimuli as diverse as light, ions, small molecules, peptides and proteins and are the targets for many pharmaceuticals. Most GPCR ligands are believed to activate (agonists) or inhibit (competitive antagonists) receptor signalling by binding the receptor at the same site as the endogenous agonist, the orthosteric site. In contrast, allosteric ligands modulate receptor function by binding to different regions in the receptor, allosteric sites. In recent years, combinatorial chemistry and high throughput screening have helped identify several allosteric GPCR modulators with novel structures, several of which already have become valuable pharmacological tools and may be candidates for clinical testing in the near future. This mini review outlines the current status and perspectives of allosteric modulation of GPCR function with emphasis on the pharmacology of endogenous and synthesised modulators, their receptor interactions and the therapeutic prospects of allosteric ligands compared to orthosteric ligands. (C) 2004 Published by Elsevier B.V.
引用
收藏
页码:407 / 420
页数:14
相关论文
共 107 条
[1]   Allosteric modulation of the human 5-HT7A receptor by lipidic amphipathic compounds [J].
Alberts, GL ;
Chio, CL ;
Im, WB .
MOLECULAR PHARMACOLOGY, 2001, 60 (06) :1349-1355
[2]   Dimerization: An emerging concept for G protein-coupled receptor ontogeny and function [J].
Angers, S ;
Salahpour, A ;
Bouvier, M .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2002, 42 :409-435
[3]  
Bailey WJ, 2001, EXPERT OPIN THER PAT, V11, P1861
[4]   Positive allosteric modulator of the human 5-HT2C receptor [J].
Bin Im, W ;
Chio, CL ;
Alberts, GL ;
Dinh, DM .
MOLECULAR PHARMACOLOGY, 2003, 64 (01) :78-84
[5]  
Birdsall NJM, 1999, MOL PHARMACOL, V55, P778
[6]   Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes [J].
Birdsall, NJM ;
Farries, T ;
Gharagozloo, P ;
Kobayashi, S ;
Kuonen, D ;
Lazareno, S ;
Popham, A ;
Sugimoto, M .
LIFE SCIENCES, 1997, 60 (13-14) :1047-1052
[7]   Allosteric site on muscarinic acetylcholine receptors: A single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands [J].
Buller, S ;
Zlotos, DP ;
Mohr, K ;
Ellis, J .
MOLECULAR PHARMACOLOGY, 2002, 61 (01) :160-168
[8]   BAY36-7620:: A potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. [J].
Carroll, FY ;
Stolle, A ;
Beart, PM ;
Voerste, A ;
Brabet, I ;
Mauler, F ;
Joly, C ;
Antonicek, H ;
Bockaert, J ;
Müller, T ;
Pin, JP ;
Prézau, L .
MOLECULAR PHARMACOLOGY, 2001, 59 (05) :965-973
[9]   G protein-coupled receptor allosterism and complexing [J].
Christopoulos, A ;
Kenakin, T .
PHARMACOLOGICAL REVIEWS, 2002, 54 (02) :323-374
[10]   INHIBITORY EFFECT OF GALLAMINE ON MUSCARINIC RECEPTORS [J].
CLARK, AL ;
MITCHELSON, F .
BRITISH JOURNAL OF PHARMACOLOGY, 1976, 58 (03) :323-331